• Innovative Company SHIONOGI

What's New

  • Show All
2017/05/18
Audio Webcasting of FY2016 Financial Results
2017/05/10
FY2016 Financial Results
2017/04/25
Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
2017/04/25
Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin
2017/04/24
Notice of Revisions to Dividend Forecasts
2017/04/18
Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin, and S-033188 a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
2017/04/13
Regarding the Application for Manufacture and Sales Approval of “Lisdexamfetamine Dimesylate”, a Therapeutic Agent for Attention Deficit Hyperactivity Disorder
2017/03/30
Symproic® (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan
2017/03/30
Acquisition of Manufacturing & Marketing Approval for the attention deficit/hyperactivity disorder (AD/HD) therapeutic agent ‘INTUNIV® Tablets 1 mg/3 mg’
2017/03/28
Shionogi Submits New Drug Application in Japan of S-524101 for Allergen Immunotherapy Treatment of Pediatric Allergic Rhinitis by House Dust Mite
2017/03/24
Audio Webcasting of the R&D Meeting
2017/03/24
EMA Accepts MAA Submission of Shionogi’s Naldemedine for the Treatment of Opioid-Induced Constipation
2017/03/24
FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain